In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality worldwide, posing a major challenge to health systems. There are a variety of ...
The global animal drug compounding market is growing steadily, expected to be valued at around US$1.5 in 2026 and projected to reach US$2.3 by 2033, with a CAGR of 6.6% in the coming years. This ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong ...
The European panel has expanded delivery options for multiple myeloma by approving a subcutaneous (SC) option for a key anti‑CD38 myeloma therapy. At its March 2026 meeting, the European Medicines ...
Covalent-organic frameworks (COFs) and metal-organic frameworks (MOFs) have been a promising carrier for drug delivery because of excellent biocompatibility, developed porous structure and sufficient ...
Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million. OrbiMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results